Detalles de la búsqueda
1.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol;
186: 182-190, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38718741
2.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol;
184: 168-177, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325276
3.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol;
2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38501262
4.
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial).
Int J Gynecol Cancer;
2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38479803
5.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Cancer;
129(12): 1846-1855, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060236
6.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol;
178: 119-129, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862791
7.
Safety and management of niraparib monotherapy in ovarian cancer clinical trials.
Int J Gynecol Cancer;
33(6): 971-981, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792166
8.
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Int J Gynecol Cancer;
33(6): 929-936, 2023 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759001
9.
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Int J Gynecol Cancer;
33(11): 1733-1742, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37931976
10.
Outcomes and endpoints of relevance in gynecologic cancer clinical trials.
Int J Gynecol Cancer;
33(3): 323-332, 2023 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36878559
11.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer;
33(4): 562-570, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564099
12.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Lancet Oncol;
23(8): e374-e384, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35901833
13.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med;
381(25): 2416-2428, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31851799
14.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med;
381(25): 2391-2402, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562799
15.
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
BMC Cancer;
22(1): 1150, 2022 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348385
16.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol;
164(2): 254-264, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34952708
17.
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Gynecol Oncol;
166(3): 494-502, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35851489
18.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol;
166(1): 36-43, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550709
19.
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
Future Oncol;
18(23): 2505-2536, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35791804
20.
EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study).
Future Oncol;
18(31): 3481-3492, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36066851